Skip to main content
ENANTA PHARMACEUTICALS INC logo

ENANTA PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · ENTA ISIN · US29251M1062 LEI · 529900SSN4DODDQSN594 US Manufacturing
Filings indexed 812 across all filing types
Latest filing 2024-12-09 Investor Presentation
Country US United States of America
Listing US ENTA

About ENANTA PHARMACEUTICALS INC

https://www.enanta.com/

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule drugs, with a focus on virology and immunology. The company utilizes a robust, chemistry-driven approach to create novel oral therapeutics for diseases with high unmet medical needs. Enanta has a significant track record of success, having developed protease inhibitors that are key components of treatment regimens for chronic hepatitis C virus (HCV) infection, which have cured over one million patients. Its current clinical pipeline is primarily focused on developing treatments for respiratory syncytial virus (RSV) and advancing its immunology programs for inflammatory diseases.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 9, 2024, reporting positive topline data from a Phase 2 pediatric study of a drug candidate. It includes a press release and a slide presentation as exhibits. The content focuses on announcing clinical trial results and providing a presentation of topline data. There are no detailed financial statements or comprehensive financial analysis typical of an Annual Report (10-K) or Interim Report (IR). The document is primarily an announcement of clinical trial results and includes a presentation, which fits the description of an Investor Presentation (IP). The length (over 10,000 characters) and detailed data support that this is more than a brief announcement, but rather a detailed presentation of study results. Therefore, the best classification is Investor Presentation (IP).
2024-12-09 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-12-03 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-12-03 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-12-03 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-12-03 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-12-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.